OLD National Bancorp IN Has $256,000 Stock Position in Balchem Co. (NASDAQ:BCPC)

OLD National Bancorp IN cut its stake in shares of Balchem Co. (NASDAQ:BCPC) by 4.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,457 shares of the basic materials company’s stock after selling 61 shares during the period. OLD National Bancorp IN’s holdings in Balchem were worth $256,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in BCPC. BNP Paribas Financial Markets grew its stake in shares of Balchem by 21.8% in the first quarter. BNP Paribas Financial Markets now owns 37,117 shares of the basic materials company’s stock valued at $5,751,000 after acquiring an additional 6,652 shares in the last quarter. Janus Henderson Group PLC boosted its holdings in Balchem by 21.3% in the 1st quarter. Janus Henderson Group PLC now owns 18,059 shares of the basic materials company’s stock valued at $2,795,000 after purchasing an additional 3,176 shares during the period. Quantbot Technologies LP acquired a new position in shares of Balchem during the 1st quarter worth approximately $495,000. William Blair Investment Management LLC increased its holdings in shares of Balchem by 8.4% during the second quarter. William Blair Investment Management LLC now owns 233,831 shares of the basic materials company’s stock worth $35,998,000 after purchasing an additional 18,104 shares during the period. Finally, Oppenheimer Asset Management Inc. raised its position in shares of Balchem by 22.1% in the second quarter. Oppenheimer Asset Management Inc. now owns 20,582 shares of the basic materials company’s stock valued at $3,169,000 after buying an additional 3,732 shares in the last quarter. Institutional investors own 87.91% of the company’s stock.

Balchem Stock Performance

NASDAQ BCPC opened at $166.76 on Thursday. Balchem Co. has a 1 year low of $110.74 and a 1 year high of $186.03. The firm has a market capitalization of $5.41 billion, a price-to-earnings ratio of 47.11, a P/E/G ratio of 5.43 and a beta of 0.65. The company has a current ratio of 2.83, a quick ratio of 1.79 and a debt-to-equity ratio of 0.26. The firm’s 50 day simple moving average is $171.60 and its 200 day simple moving average is $162.09.

Balchem (NASDAQ:BCPC) last issued its quarterly earnings results on Friday, July 26th. The basic materials company reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.95 by $0.03. Balchem had a return on equity of 10.94% and a net margin of 12.52%. The company had revenue of $234.08 million for the quarter, compared to analyst estimates of $241.26 million. As a group, research analysts expect that Balchem Co. will post 3.96 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, SVP Gunsteren Job Leonard Van sold 7,750 shares of Balchem stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $180.05, for a total transaction of $1,395,387.50. Following the sale, the senior vice president now directly owns 8,540 shares of the company’s stock, valued at approximately $1,537,627. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 1.25% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the company. HC Wainwright raised their price objective on Balchem from $170.00 to $185.00 and gave the stock a “buy” rating in a research note on Wednesday, July 31st. StockNews.com downgraded Balchem from a “buy” rating to a “hold” rating in a research note on Monday, July 29th.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.